Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

NCT04227015 is registered in ClinicalTrials.gov with He Huang as lead sponsor.

NCT NCT04227015
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04227015 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy
Lead sponsor
He Huang
Phase
Phase 1
Overall status
Recruiting
Start date
January 8, 2020
Completion date
May 31, 2027
Enrollment
72 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, non-hodgkin lymphoma